Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price29.16 USD
Fair value43.75
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Markup26.20+11.3% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Concentrix Corporation holds its Markup at $29.16. The statistical read favours the sellers, held for 7 days.
As held on the ledger · 2026-09-16
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 7 days
Price at the screen
$29.16
Valuation
N/A trailing · 2.45 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.46
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
43.10%
Below 33%
Interest-bearing debt is 43.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
13.13%
Below 49%
Money owed to the company is 13.1% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-16 screen. The gold marker is the market price at the same screen. A 50.0% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits +20% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cheap valuation hides losses at customer service giant
Every company needs someone to handle the calls, chats and complaints that keep customers happy, and Concentrix runs that operation for brands worldwide. Yet the business is shrinking in real terms, posting a 13 percent negative profit margin and a 38 percent negative return on equity while revenue edges up just 2 percent. We pass, despite the ethical screen clearing and a forward multiple of only 2.1 times.
The market already prices in trouble, with shares at 24 dollars against analyst targets around 35 dollars, and our own fair value sits higher but the opportunity rating stays at none. A rock-bottom multiple on collapsing earnings is rarely the bargain it appears.
Risk sits in the operating losses and thin growth that point to structural pressure on margins and clients, not a temporary dip. The low multiple reflects reality more than opportunity. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CNXC trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-19Markup$29.16+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-18Markup$29.16+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-17Markup$29.16+19.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup$24.51+0.3%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it none, with a mean price target of $41.
2026-07-25Markup$24.43-6.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 6.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it none, with a mean price target of $41.
2026-07-18Markup$26.20+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it none, with a mean price target of $41.
2026-07-03Markup$26.20+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$26.20Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
